STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #572 by analyst upside · 2026-06-27
PHAR
Pharming Group N.V.
Healthcare · Market Cap $942M · P/E 70.2x
ANALYST PRICE TARGET
+157.5%
implied upside to consensus target
Current Price $13.34
Consensus Target $34.35
Bull Target $40.0
Bear Target $23.4
Analysts Covering 4
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
4
Hold
0
Sell
0
52-Week Low $9.54
52-Week High $21.34
YTD Return -22.2%
FUNDAMENTALS
Market Cap $942M
P/E Ratio (TTM) 70.2x
Forward P/E 203.7x
EPS (TTM) $0.19
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $369M
Profit Margin 3.3%
52-WEEK RANGE
52-Week Low $9.54
52-Week High $21.34
Current Price $13.34
Bear Target $23.4
Bull Target $40.0
● Now $13.34 ● Target $34.35
TRADING DATA
Avg Volume 12K
YTD Return -22.2%
Analyst Count 4
Consensus Buy
Upside to Target +157.5%
Last Updated 2026-06-27

ANALYST SUMMARY

Pharming Group N.V. (PHAR) is currently trading at $13.34 with a Wall Street consensus price target of $34.35, implying potential upside of 157.5% over the next 12 months. 4 analysts currently cover PHAR, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $40.0, while the most cautious has a target of $23.4.

PHAR operates in the Healthcare sector with a market capitalisation of $942M. The stock is down 22.2% year-to-date and is currently trading near the lower end of its 52-week range of $9.54 – $21.34.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for PHAR, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Canaccord Genuity ● Initiated
Buy 2026-04-10 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-03-24 31% win rate (48 calls)
Oppenheimer reit
Outperform → Outperform 2026-03-13 14% win rate (7 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-03-21 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-03-20 31% win rate (48 calls)
Oppenheimer — Reiterated
Outperform → Outperform 2025-03-14 14% win rate (7 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-03-14 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2024-12-17 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
44
out of 100
Coverage depth
12/30
Consensus clarity
5/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →